Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2017 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017

New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...
November 02, 2017 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum

Ran Nussbaum, managing partner and co-founder of The Pontifax Group, joins VBI Board of DirectorsPontifax’s participation in the recent financing was alongside investments from several new fundamental...
October 31, 2017 08:30 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares

CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
October 30, 2017 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million

CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
October 26, 2017 09:29 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million

CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
October 25, 2017 16:01 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares

CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
May 09, 2016 15:02 ET | Source: VBI Vaccines, Inc.

Additional Details Relating to the SciVac Therapeutics and VBI Vaccines Merger Transaction

SciVac Therapeutics changed its name to VBI VaccinesOn May 6, 2016, each share of VBI Vaccines common stock was converted into the right to receive 0.520208 common shares of post-merger VBI VaccinesOn...
May 09, 2016 08:30 ET | Source: VBI Vaccines, Inc.

SciVac Therapeutics and VBI Vaccines Announce Completion of Merger Transaction

SciVac Therapeutics changes its name to VBI VaccinesCombined company to begin trading on The NASDAQ Capital Market under the symbol “VBIV”Combined company is a biotechnology company with a licensed...
April 28, 2016 08:30 ET | Source: VBI Vaccines, Inc.

VBI Vaccines to Present at the Bloom Burton Healthcare Investor Conference

CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”) is scheduled to present at the Bloom Burton Healthcare Investor Conference on Monday, May 2nd at 1:30 PM...
April 14, 2016 08:30 ET | Source: VBI Vaccines, Inc.

VBI Vaccines and SciVac Therapeutics Announce Effectiveness of Registration Statement on Form F-4

CAMBRIDGE, Mass., April 14, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”) and SciVac Therapeutics Inc. (TSX:VAC) (OTCQX:SVACF) (“SciVac”) announced today that the registration...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right